| 1 | Anti-von Willebrand Factor Nanobody, Caplacizumab (Synonym: Cablivi (TN)) | [2] Caplacizumab Caplacizumab (Synonym: Cablivi), Von Willebrand factor human | [1] D11160
D11160
(Name: Cablivi (TN)) | [1] VWF VWF 💬 | [8] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | [1] 64 64 |
| 2 | Anti-von Willebrand Factor Nanobody, INN = Caplacizumab (Synonym: Cablivi (TN)) | [2] Caplacizumab Caplacizumab (Synonym: Cablivi), Von Willebrand factor human | [1] D11160
D11160
(Name: Cablivi (TN)) | [1] VWF VWF 💬 | [8] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | [1] 64 64 |
| 3 | CABLIVI | [1] Caplacizumab Caplacizumab (Synonym: Cablivi) | [1] D11160
D11160
(Name: Cablivi (TN)) | [1] VWF VWF 💬 | [8] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | [1] 64 64 |
| 4 | Cablivi® | [1] Caplacizumab Caplacizumab (Synonym: Cablivi) | [1] D11160
D11160
(Name: Cablivi (TN)) | [1] VWF VWF 💬 | [8] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | [1] 64 64 |
| 5 | CAPLACIZUMAB (Synonym: Cablivi (TN)) | [1] Caplacizumab Caplacizumab (Synonym: Cablivi) | [1] D11160
D11160
(Name: Cablivi (TN)) | [1] VWF VWF 💬 | [8] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | [1] 64 64 |
| 6 | Caplacizumab (ALX-0081) (Synonym: Cablivi (TN)) | [1] Caplacizumab Caplacizumab (Synonym: Cablivi) | [1] D11160
D11160
(Name: Cablivi (TN)) | [1] VWF VWF 💬 | [8] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | [1] 64 64 |
| 7 | Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081) (Synonym: Cablivi (TN)) | [2] Caplacizumab Caplacizumab (Synonym: Cablivi), Von Willebrand factor human | [1] D11160
D11160
(Name: Cablivi (TN)) | [1] VWF VWF 💬 | [8] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | [1] 64 64 |
| 8 | Caplacizumab (an anti-von Willebrand Factor Nanobody) (Synonym: Cablivi (TN)) | [2] Caplacizumab Caplacizumab (Synonym: Cablivi), Von Willebrand factor human | [1] D11160
D11160
(Name: Cablivi (TN)) | [1] VWF VWF 💬 | [8] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | [1] 64 64 |